Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SmithKline Beecham

This article was originally published in The Tan Sheet

Executive Summary

Andrew Bonfield will succeed Hugh Collum as chief financial officer at year-end, SB announces Sept. 10. Bonfield is deputy finance officer and senior VP-corporate controller. He joined the firm in 1989 from Price Waterhouse and worked on the merger of SmithKline Beckman and Beecham Labs. In 1991, he became director and VP-corporate accounts, the youngest VP in the company's history. Bonfield, 36, was appointed deputy finance director in 1997. SB's delay in announcing Collum's successor encouraged speculation his departure stems from uncertainty about the company's strategic direction. SB maintains there is no connection and notes Collum's departure is part of his "long-planned retirement"

Andrew Bonfield will succeed Hugh Collum as chief financial officer at year-end, SB announces Sept. 10. Bonfield is deputy finance officer and senior VP-corporate controller. He joined the firm in 1989 from Price Waterhouse and worked on the merger of SmithKline Beckman and Beecham Labs. In 1991, he became director and VP-corporate accounts, the youngest VP in the company's history. Bonfield, 36, was appointed deputy finance director in 1997. SB's delay in announcing Collum's successor encouraged speculation his departure stems from uncertainty about the company's strategic direction. SB maintains there is no connection and notes Collum's departure is part of his "long-planned retirement".

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel